Literature DB >> 3001726

Characterization of solubilized human and rat brain beta-endorphin-receptor complex.

D M Helmeste, C H Li.   

Abstract

Opioid receptors have been solubilized from human striatal and rat whole-brain membranes by use of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Tritiated human beta-endorphin (3H-beta h-EP) binding revealed high-affinity competition by morphine, naloxone, and various beta-EP analogues, suggesting predominantly mu-type binding. Lack of high-affinity competition by (+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneaceta mide methanesulfonate (U50-488, Upjohn) indicated that kappa sites were not labeled by 3H-beta h-EP under these conditions. Affinities were similar in both soluble and membrane preparations except for [Met]enkephalin, which appears to be rapidly degraded by the solubilized extract. Size differences between human and rat solubilized 3H-beta h-EP-receptor complexes were revealed by exclusion chromatography.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3001726      PMCID： PMC322792          DOI： 10.1073/pnas.83.1.67

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  17 in total

1.  beta-Endorphin: characteristics of binding sites in the rat brain.

Authors:  P Ferrara; R Houghten; C H Li
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

2.  Two distinct enkephalinases: solubilization, partial purification and separation from angiotensin converting enzyme.

Authors:  C Gorenstein; S H Snyder
Journal:  Life Sci       Date:  1979 Dec 10-17       Impact factor: 5.037

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  On the degradation of enkephalins and endorphins by rat and mouse brain extracts.

Authors:  N Marks; A Grynabaum; A Neidle
Journal:  Biochem Biophys Res Commun       Date:  1977-02-21       Impact factor: 3.575

5.  Synthesis and analgesic activity of human beta-endorphin.

Authors:  C H Li; D Yamashiro; L F Tseng; H H Loh
Journal:  J Med Chem       Date:  1977-03       Impact factor: 7.446

6.  Specific non-opiate binding sites for human beta-endorphin on the terminal complex of human complement.

Authors:  L Schweigerer; S Bhakdi; H Teschemacher
Journal:  Nature       Date:  1982-04-08       Impact factor: 49.962

7.  A nondenaturing zwitterionic detergent for membrane biochemistry: design and synthesis.

Authors:  L M Hjelmeland
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

8.  Properties and localization of beta-endorphin receptor in rat brain.

Authors:  P Y Law; H H Loh; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

9.  Preparation and properties of tritiated human beta-endorphin with high specific radioactivity.

Authors:  R A Houghten; C H Li
Journal:  Int J Pept Protein Res       Date:  1978-11

10.  Binding of 3H-beta-endorphin to rat brain membranes: characterization of opiate properties and interaction with ACTH.

Authors:  H Akil; W A Hewlett; J D Barchas; C H Li
Journal:  Eur J Pharmacol       Date:  1980-05-30       Impact factor: 4.432
View more
  2 in total

1.  Preparation of [125I-Tyr27,Leu5]beta h-endorphin and its use for crosslinking of opioid binding sites in human striatum and NG108-15 neuroblastoma-glioma cells.

Authors:  D M Helmeste; R G Hammonds; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

2.  CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.

Authors:  Mohab M Ibrahim; Frank Porreca; Josephine Lai; Phillip J Albrecht; Frank L Rice; Alla Khodorova; Gudarz Davar; Alexandros Makriyannis; Todd W Vanderah; Heriberto P Mata; T Philip Malan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-10       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.